RP3

Replimune to Host Virtual Investor Event on December 7, 2022

Retrieved on: 
Tuesday, November 22, 2022
MOA, Skin cancer, Immunogenic cell death, TME, RP2, Safety, Melanoma, Patient, Neoplasm, Tumor microenvironment, RP1, Bristol Myers Squibb, Nivolumab, Webcast, RP3, RPX, Antigen, Pharmaceutical industry

Additionally, the company will review the commercial opportunity in skin cancer with RP1.

Key Points: 
  • Additionally, the company will review the commercial opportunity in skin cancer with RP1.
  • The Company will also provide an update on its RP2 and RP3 program.
  • The event will begin at 8:00 a.m. Eastern Time on Wednesday, December 7, 2022.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022
Goal, Melanoma, Securities Exchange Act of 1934, NASDAQ, Bristol Myers Squibb, Herpes simplex virus, PFS, Breast cancer, CD40L, Marketing, RP3, CRC, RP1, Protein, RP2, Safety, FDA, Cancer, Antigen, Immunogenic cell death, NSCLC, GLOBE, U.S. Securities and Exchange Commission, Colorectal cancer, Sale, Coronavirus, Large-cell lung carcinoma, MOA, Neck, GI, SCCHN, RPX, Neoplasm, Lung cancer, Head, HCC, CSCC, Patient, Review, Hepatocellular carcinoma, ORR, Uveal melanoma, Clinical trial, Securities Act of 1933, Drug Quality and Security Act, Skin, Security (finance), D, CR, MSI, Lymph, Company, Progression-free survival, Program, Tumor microenvironment, Investment, Forward-looking statement, Research, Toxicity, TME, Squamous cell carcinoma, Pharmaceutical industry, Medical imaging, Vaccine, Nivolumab, Sanofi, Regeneron Pharmaceuticals

WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • Our ambition to establish a major skin cancer franchise, built off of our lead RP1 program, is progressing to plan.
  • R&D Expenses: Research and development expenses were$29.5 millionfor the first quarter ended June 30, 2022, as compared to$18.6 millionfor the first quarter ended June 30, 2021.
  • S,G&A Expenses: Selling, general and administrative expenses were$11.4 millionfor the first quarter endedJune 30, 2022, as compared to$8.8 millionfor the first quarter endedJune 30, 2021.
  • Our actual results could differ materially from the results described in or implied by such forward-looking statements.

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
MOA, Herpes simplex virus, Immunogenic cell death, Neoplasm, U.S. Securities and Exchange Commission, Nasdaq, Tumor microenvironment, Progression-free survival, REPL, Patient, Goal, HSV, CSCC, TME, Review, Coronavirus, ORR, Clinical trial, Society, American Society of Clinical Oncology, RP1, CD40L, NSCLC, RP3, Securities Act of 1933, PFS, Securities Exchange Act of 1934, RP2, RPX, Bristol Myers Squibb, Toxicity, Antigen, Forward-looking statement, Safety, ASCO, Large-cell lung carcinoma, Drug Quality and Security Act, Nivolumab, Protein, Lymph, CR, Security (finance), Melanoma, GLOBE, Pharmaceutical industry, Vaccine, Sanofi, Regeneron Pharmaceuticals

WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.

Key Points: 
  • WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.
  • The clinical trial is enrolling 180 patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) who are nave to anti-PD-1 therapy.
  • The study is being conducted under a clinical trial collaboration agreement with Regeneron in which the costs of the trial are shared and full commercial rights retained by Replimune.
  • There are 4 tumor specific cohorts currently enrolling in this clinical trial including a 125-patient cohort in anti-PD-1 failed cutaneous melanoma.

Fayetteville PWC and Bloom Energy to Transform Waste into Clean Community Electricity

Retrieved on: 
Thursday, May 5, 2022
Oil, Gas, Alternative Energy, Energy, Other Energy, Utilities, Diamond, Forward-looking statement, Private Securities Litigation Reform Act, Carbon, American Public Power Association, NYSE, Hydrogen, Power, RP3, Bloom Energy, Annual report, Groundwater, Electricity, Methane, Drinking water, Achievement, Air pollution, SEC, CEO, PWC, City, Renewable energy, Natural gas

As nations and cities continue to grow and urbanize, waste generation is expected to increase by 70 percent by 2050. Currently, waste gas generated from the wastewater treatment process and landfills is flared, a commonly used and controlled method for releasing the gas into the atmosphere, which contributes to air pollution. By reducing biogas flaring at the wastewater and landfill facilities, local emissions are averted, helping to improve air quality. The project will also use methane -- a potent greenhouse gas that accounts for 50 to 70 percent of biogas – from swine farms that would otherwise be released into the atmosphere.

Key Points: 
  • Creating renewable energy from multiple biogas streams in the region, the new project will reduce emissions and advance the Fayetteville communitys efforts to meet North Carolinas clean energy standards.
  • Hoffer Water Treatment Facility will be one of the first of its kind to blend multiple waste gas sources to produce clean, carbon-neutral electricity.
  • Bloom Energys fuel cells will complement PWCs existing renewable energy sources, helping meet PWCs North Carolina Renewable Energy and Energy Efficiency Portfolio Standard requirements.
  • PWC is excited to collaborate with Bloom Energy to bring a first-of-its kind clean energy project to our community to serve our customers, said Elaina Ball, CEO and general manager, PWC.

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 3, 2022
Large-cell lung carcinoma, Breast, Progression-free survival, NMSC, Coronavirus, RP3, Goal, Securities Act of 1933, Skin cancer, Antigen, CR, GLOBE, Skin, RPX, U.S. Securities and Exchange Commission, Review, RP1, Annual general meeting, CSCC, Marketing, Neoplasm, Company, Herpes simplex virus, TME, Investment, Securities Exchange Act of 1934, Security (finance), Research, Bristol Myers Squibb, Toxicity, NASDAQ, Clinical trial, D, Tumor microenvironment, Nivolumab, Immunogenic cell death, Immunotherapy, NSCLC, MOA, Melanoma, FDA, Protein, Safety, Forward-looking statement, Patient, RP2, Lung, Gastrointestinal cancer, Lymph, SITC, PFS, ORR, CD40L, Head, Drug Quality and Security Act, Liver disease, Pharmaceutical industry, Medical imaging, Airline, Vaccine, Sanofi, Regeneron Pharmaceuticals

WOBURN, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2021 and provided a business update.

Key Points: 
  • The Company will also provide a detailed overview of its RP2/3 program including the Phase 2 development plan.
  • The Company expects to present initial data from this clinical trial in the first quarter of 2022.
  • G&A Expenses: General and administrative expenses were$10.3 millionfor the third quarter endedDecember 31, 2021, as compared to$6.0 millionfor the third quarter endedDecember 31, 2020.
  • Our actual results could differ materially from the results described in or implied by such forward-looking statements.

Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones

Retrieved on: 
Monday, January 10, 2022
Drug Quality and Security Act, Neoplasm, Protein, Securities Exchange Act of 1934, RP3, Securities Act of 1933, U.S. Securities and Exchange Commission, Lung, Toxicity, Nivolumab, Large-cell lung carcinoma, REPL, TME, Melanoma, Security (finance), Goal, RPX, Skin, MOA, Company, ORR, CSCC, Herpes simplex virus, Progression-free survival, Head, Clinical trial, Safety, RP2, PFS, Antigen, Investor, Liver, Patient, Immunogenic cell death, RP1, Skin cancer, CD40L, Nasdaq, Gastrointestinal cancer, GLOBE, Liver disease, NMSC, NSCLC, Tumor microenvironment, Coronavirus, Conference, Cancer, CR, Bristol Myers Squibb, Forward-looking statement, Lymph, Review, Breast, Pharmaceutical industry, Medical imaging, Vaccine, Regeneron Pharmaceuticals, Sanofi

WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today provided a corporate update, highlighting the progress of key programs.

Key Points: 
  • Data with RP1 in various high-value skin cancer indications has continued to mature in 2021, said Philip Astley-Sparke, Chief Executive Officer of Replimune.
  • The Company expects to complete enrollment such that the trigger for the primary data analysis is expected in late 2022.
  • The company expects to release interim data from this cohort in late 2022.
  • The Company remains on track to present initial data from this clinical trial in the first quarter of 2022.

New Power Provider Serves Appalachian State University’s New River Light & Power

Retrieved on: 
Wednesday, January 5, 2022
Education, Utilities, Environment, Coal, Alternative Energy, Energy, University, PPA, Professional, Electricity, Review, CPP, RP3, Appalachian State University, City, Power, University, State university system, Â, Town, Partnership, American Public Power Association, Sawmill, Renewable energy

The new year marked a change in electric service providers for Appalachian State Universitys electric utility, New River Light and Power (NRLP).

Key Points: 
  • The new year marked a change in electric service providers for Appalachian State Universitys electric utility, New River Light and Power (NRLP).
  • Carolina Power Partners (CPP), the leading independent wholesale electric provider in the Carolinas, began delivering reliable, low-cost power to NRLP on January 1, 2022.
  • We are extremely proud to start our full requirement energy service for Appalachian State University, said TJ Higgins, CPPs Asset Manager.
  • For more than 100 years, Appalachian State Universitys nonprofit electric utility NRLP has provided power to Western North Carolina.

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 4, 2021
Safety, NMSC, Head, Neoplasm, U.S. Securities and Exchange Commission, Interim, Clinical trial, PFS, Drug Quality and Security Act, D, GLOBE, RP3, SITC, Securities Exchange Act of 1934, Liver, Lung, CSCC, Colorectal cancer, Security (finance), Skin, Company, Investment, Herpes simplex virus, Nivolumab, Liver disease, Toxicity, Biotechnology, Skin cancer, Goal, RP2, Immunotherapy, Bristol Myers Squibb, Large-cell lung carcinoma, CD40L, Breast, ORR, Protein, CEO, CR, Melanoma, Annual general meeting, Squamous cell carcinoma, Cancer, Securities Act of 1933, NSCLC, Poster, Gastrointestinal cancer, Patient, NASDAQ, FDA, Review, Lymph, Forward-looking statement, Research, Therapy, Coronavirus, Progression-free survival, Pharmaceutical industry, Medical imaging, Vaccine

WOBURN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced financial results for the fiscal second quarter ended September 30, 2021 and provided a business update.

Key Points: 
  • R&D Expenses: Research and development expenses were$19.9 millionfor the second quarter ended September 30, 2021, as compared to$14.1 millionfor the second quarter ended September 30, 2020.
  • G&A Expenses: General and administrative expenses were$9.3 millionfor the second quarter endedSeptember 30, 2021, as compared to$5.6 millionfor the second quarter endedSeptember 30, 2020.
  • Net Loss: Net loss was$29.4 millionfor the second quarter endedSeptember 30, 2021, as compared to a net loss of$20.1 millionfor the second quarter endedSeptember 30, 2020.
  • Our actual results could differ materially from the results described in or implied by such forward-looking statements.